Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Triciribine||VQD-002|API-2||Akt Inhibitor (Pan) 18||Triciribine (API-2) is a purine analog that inhibits DNA synthesis, and blocks Akt phosphorylation, which may reduce proliferation and promote apoptosis in cancer cells (PMID: 21636709, PMID: 19422047).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|AKT1 act mut||Advanced Solid Tumor||no benefit||Triciribine||Phase I||Actionable||In a Phase I trial, Triciribine (API-2) demonstrated safety, but lacked efficacy as a monotherapy in advanced solid tumor patients with activated Akt (PMID: 20644979).||20644979|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|